Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ.

Abstract

We treated a 61-year-old patient with a diagnosis of bilateral ureteral carcinoma in situ with percutaneous perfusions of mitomycin C. After 16 sessions of mitomycin C therapy instilled through bilateral nephrostomy tubes, the urine cytology results became negative for malignancy. Bilateral ureteroscopy and cold-cup punch biopsies of the ureter revealed no evidence of disease. The patient did not experience side effects. He has remained free of disease during a 12-month follow-up period. Percutaneous perfusion of mitomycin C appears to be one of the effective and safe treatments for the carcinoma in situ of the upper urinary tract.

• Authors: T Amano, K Naito, K Koshida, K Kunimi, H Morishita, H Hisazumi
• Journal: Urologia internationalis (Urol Int) Vol. 51 Issue 1 Pg. 46-8 ( 1993) ISSN: 0042-1138 [Print] Switzerland
• PMID: 8333091 (Publication Type: Case Reports, Journal Article)

Chemical References

• Mitomycin
• Vinblastine
• Doxorubicin
• Cisplatin
• Methotrexate

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma in Situ (drug therapy)
• Cisplatin (administration & dosage)
• Doxorubicin (administration & dosage)
• Humans
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Mitomycin (administration & dosage, therapeutic use)
• Nephrostomy, Percutaneous
• Time Factors
• Ureteral Neoplasms (drug therapy)
• Vinblastine (administration & dosage)